The effect of baseline testosterone on the efficacy of degarelix and leuprolide: Further insights from a 12-month, comparative, phase III study in prostate cancer patients

Urology

Volumn 80, Issue 1, 2012, Pages 174-181

  Damber, Jan Erik ^a   Tammela, Teuvo L J ^b   Iversen, Peter ^c   Abrahamsson, Per Anders ^d   Boccon Gibod, Laurent ^e   Olesen, Tine Kold ^f   Van Der Meulen, Egbert ^f   Persson, Bo Eric ^f  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d LUND UNIVERSITY   (Sweden)

^e BICHAT HOSPITAL   (France)

^f Ferring Pharmaceuticals AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEGARELIX; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SURGE CAPACITY; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84862983937     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.01.092     Document Type: Article

References (30)

1. A. Heidenreich, M. Bolla, S. Joniau Guidelines on prostate cancer Eur Assoc Urol 2011 2011 1 152 http://www.uroweb.org/gls/pdf/08-Prostate-Cancer.pdf Accessed: August 2011
2. L. Klotz, L. Boccon-Gibod, N.D. Shore The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531 1538
3. J. Waxman, A. Man, W.F. Hendry Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer Br Med J (Clin Res Ed) 291 1985 1387 1388 (Pubitemid 16212355)
4. I.M. Thompson, E.J. Zeidman, F.R. Rodriguez Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate J Urol 144 1990 1479 1480
5. B. Tombal Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 4 2005 14 19 (Pubitemid 40780974)
6. J. Anderson, P.A. Abrahamsson, D. Crawford Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 101 2008 1497 1501 (Pubitemid 351704035)
7. P.H. Gann, C.H. Hennekens, J. Ma Prospective study of sex hormone levels and risk of prostate cancer Natl Cancer Inst 88 1996 1118 1126 (Pubitemid 26274606)
8. T. Shaneyfelt, R. Husein, G. Bubley Hormonal predictors of prostate cancer: a meta-analysis J Clin Oncol 18 4 2000 847 853 (Pubitemid 30106616)
9. T. Imamoto, H. Suzuki, K. Akakura Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer Endocr J 48 2001 573 578 (Pubitemid 33035347)
10. G.K. Zagars, A. Pollack, A.C. von Eschenbach Serum testosterone - a significant determinant of metastatic relapse for irradiated localized prostate cancer Urology 49 1997 327 334 (Pubitemid 27138671)
11. T. Imamoto, H. Suzuki, M. Yano The role of testosterone in the pathogenesis of prostate cancer Int J Urol 15 2008 472 480 (Pubitemid 351713199)
12. A.W. Roddam, N.E. Allen Endogenous Hormones and Prostate Cancer Collaborative Group Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 3 2008 170 183 (Pubitemid 351480553)
13. M. Gittelman, P.J. Pommerville, B.E. Persson A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America J Urol 180 2008 1986 1992
14. H. Van Poppel, B. Tombal, J.J. de la Rosette Degarelix: a novel gonadotrophin-releasing hormone (GnRH) blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer Eur Urol 54 2008 805 813
15. B. Tombal, K. Miller, L. Boccon-Gibod Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 2010 836 842
16. M.S. Soloway, P.F. Schellhammer, J.A. Smith Jr. Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy J Urol 154 6 1995 2110 2114
17. N.J. Vogelzang, G.W. Chodak, M.S. Soloway Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial Zoladex Prostate Study Group Urology 46 2 1995 220 226
18. M. Perachino, V. Cavalli, F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105 5 2010 648 651
19. M. Roach 3rd, K. Bae, C. Lawton Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 78 5 2010 1314 1322
20. B. Tombal The importance of testosterone control in prostate cancer Eur Urol Suppl 6 2007 834 839 (Pubitemid 47102240)
21. B. Tombal What is new in hormone therapy for prostate cancer in 2007? Eur Urol Suppl 7 2008 477 483
22. R. Berges, U. Bello Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer Curr Med Res Opin 22 2006 649 655
23. J. Morote, A. Orsola, J. Planas Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295 (Pubitemid 47368393)
24. D. McLeod, N. Zinner, K. Tomera A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 2001 756 761
25. J. Trachtenberg, M. Gittleman, C. Steidle A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer J Urol 167 2002 1670 1674 (Pubitemid 34240698)
26. L. Boccon-Gibod, E. Van der Meulen, B.E. Persson An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer Ther Adv Urol 3 3 2011 127 140
27. J. Morote, A. Ruibal, J. Palou Clinical utility of prostatic specific antigen and prostatic acid phosphatase serum levels in monitoring prostate cancer Int J Biol Markers 3 1988 23 28
28. H. Matzkin, O. Lewyshon, D. Ayalon Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer Cancer 63 1989 1287 1291 (Pubitemid 19084547)
29. J.A. Storlie, J.C. Buckner, G.A. Wiseman Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma Cancer 76 1995 96 100
30. D.C. Smith, R.L. Dunn, M.S. Strawderman Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer J Clin Oncol 16 1998 1835 1843 (Pubitemid 28234729)